Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Emerging Microbes & Infections
- Vol. 9 (1), 2394-2403
- https://doi.org/10.1080/22221751.2020.1835448
Abstract
To understand SARS-CoV-2 immunity after natural infection or vaccination, functional assays such as virus neutralising assays are needed. So far, assays to detect SARS-CoV-2 neutralising antibodies rely on cell-culture based infection assays either using wild type SARS-CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety facilities and are difficult to standardize. Recently, a new surrogate virus neutralisation test (sVNT) was described that uses the principle of an ELISA to measure the neutralisation capacity of anti-SARS-CoV-2 antibodies directed against the receptor binding domain. Here, we performed an independent evaluation of the robustness, specificity and sensitivity on an extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples collected before 2020 and compared it to cell-based neutralisation assays. We found a high specificity of 99.2 (95%CI: 96.9-99.9) and overall sensitivity of 80.3 (95%CI: 74.9-84.8) for the sVNT. Clinical sensitivity increased between early (14 dpos/dpd) from 75.0 (64.7-83.2) to 83.1 (76.5-88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3 (56.4-86.9) and 98.2 (89.4-99.9) for titres >= 10 to = 40 to = 160 were always positive in the sVNT. In conclusion, the sVNT can be used as an additional assay to determine the immune status of COVID-19 infected of vaccinated individuals but its value needs to be assessed for each specific context.Keywords
Funding Information
- Private Foundation HUG (not applicable)
This publication has 27 references indexed in Scilit:
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Evaluation of nine commercial SARS-CoV-2 immunoassaysPublished by Cold Spring Harbor Laboratory ,2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus FusionJournal of Virology, 2019
- Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus InfectionsThe Journal of Infectious Diseases, 2017
- A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I InterferonPLOS ONE, 2011
- Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseasesArthritis Research & Therapy, 2010
- Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike proteinJournal of General Virology, 2005
- A human SARS-CoV neutralizing antibody against epitope on S2 proteinBiochemical and Biophysical Research Communications, 2005